General Information of Drug (ID: DMIFDPL)

Drug Name
AS-8112 Drug Info
Indication
Disease Entry ICD 11 Status REF
Vomiting MD90 Terminated [1]
Cross-matching ID
PubChem CID
10363531
TTD Drug ID
DMIFDPL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Dopamine D3 receptor (D3R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cariprazine DMJYDVK Bipolar disorder 6A60 Approved [3]
Pramipexole DMNMW9R Parkinson disease 8A00.0 Approved [4]
Ropinirole DMA6S1D Parkinson disease 8A00.0 Approved [4]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [5]
P2B-001 DM9PVHX Parkinson disease 8A00.0 Phase 3 [6]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [7]
ONC201 DMM5SCF Endometrial cancer 2C76 Phase 2 [8]
TAK-906 DMBQD9H Diabetic gastroparesis DA41.00 Phase 2 [9]
GSK598809 DMGU05N Drug abuse 6C4G.1Z Phase 2 [10]
GSK618334 DMJPXZ4 Drug abuse 6C4G.1Z Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 3A receptor (HTR3A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dolasetron DMMG26Z Nausea MD90 Approved [11]
Alosetron DML2A03 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [12]
Tropisetron DMNSJ7V Fibromyalgia MG30.01 Approved [13]
Palonosetron DMBHMOX Nausea MD90 Approved [14]
Levetiracetam DMTGDN8 Epilepsy 8A60-8A68 Approved [13]
Procaine DM4LSNE Anaesthesia 9A78.6 Approved [15]
Cilansetron DMP0NGX Irritable bowel syndrome DD91.0 Phase 3 [16]
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [17]
Norcisapride DMJSKUI Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [18]
YM-114 DML2IXO Nausea MD90 Discontinued in Phase 2 [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 3A receptor (HTR3A) TTPC4TU 5HT3A_HUMAN Antagonist [2]
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Antagonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009088)
2 Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
3 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
6 Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
10 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
11 Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
12 Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
13 Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
14 Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
15 Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
16 Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
17 Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
18 mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
19 Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.